Form 4: Harmony Biosciences CEO Reports Equity Transactions

Harmony Biosciences CEO Jeffrey M. Dayno reported significant equity transactions, including new stock option and RSU grants, and the vesting and tax-related disposition of previously granted RSUs.

Summary

• Jeffrey M. Dayno, President, CEO, and Director of Harmony Biosciences Holdings, Inc. (HRMY), reported several equity transactions.
• On January 22, 2026, Dayno was granted 184,600 stock options with an exercise price of $36.76, vesting over four years starting January 22, 2027, and expiring on January 22, 2036.
• Also on January 22, 2026, Dayno received a grant of 52,900 Restricted Stock Units (RSUs), vesting in four equal annual installments beginning January 22, 2027.
• On January 24, 2026, 10,500 previously granted RSUs vested, resulting in the acquisition of 10,500 shares of common stock at $0.
• Concurrently on January 24, 2026, 4,785 shares were disposed of at $36.82 to satisfy income tax withholdings related to the RSU vesting.
• On January 25, 2026, 13,000 previously granted RSUs vested, resulting in the acquisition of 13,000 shares of common stock at $0.
• Concurrently on January 25, 2026, 5,654 shares were disposed of at $36.82 to satisfy income tax withholdings related to the RSU vesting.
• Following these transactions, Dayno beneficially owns 5,715 shares directly from the January 24, 2026 transactions and 7,346 shares directly from the January 25, 2026 transactions.
• He also holds 184,600 stock options and 52,900 RSUs from the new grants, plus 21,000 RSUs (from a January 24, 2024 grant) and 39,000 RSUs (from a January 25, 2025 grant) indirectly.

Sentiment

Score: 6

Explanation: The filing reflects routine executive compensation activities, including new grants and scheduled vesting. While the grants are positive for management alignment, the tax-related dispositions are standard and do not indicate a significant shift in company performance or outlook.

Positives

• The grant of 184,600 stock options and 52,900 Restricted Stock Units (RSUs) aligns management's interests with long-term shareholder value.
• The vesting of 10,500 and 13,000 previously granted RSUs indicates the successful fulfillment of prior compensation milestones.

Negatives

• The disposition of 4,785 shares and 5,654 shares to cover tax withholdings, while routine, reduces the direct beneficial ownership of the CEO.

Future Outlook

The vesting schedules for the newly granted stock options and RSUs extend through January 2030 (for RSUs granted on January 22, 2026) and January 2036 (for stock options), indicating a long-term incentive structure for the CEO.

Industry Context

Equity compensation, including stock options and restricted stock units, is a standard practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize executive talent, aligning their performance with shareholder interests.

Comparison to Industry Standards

• The compensation structure, involving a mix of stock options and restricted stock units with multi-year vesting schedules, is consistent with common executive compensation practices in publicly traded biopharmaceutical companies.

Stakeholder Impact

• Shareholders: The equity grants align the CEO's long-term financial interests with shareholder value creation.
• Employees: Reflects standard executive compensation practices, potentially influencing broader compensation strategies.

Next Steps

• Continued vesting of 184,600 stock options, with 25% vesting on January 22, 2027, and quarterly thereafter until January 22, 2030.
• Continued vesting of 52,900 Restricted Stock Units in four equal annual installments beginning January 22, 2027.
• Continued vesting of 21,000 Restricted Stock Units (from January 24, 2024 grant) in annual installments.
• Continued vesting of 39,000 Restricted Stock Units (from January 25, 2025 grant) in annual installments.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, including new grants of stock options and restricted stock units, and the vesting of previously awarded units with associated tax withholdings. Such transactions are standard and do not typically provide new material information that would warrant a change in investment recommendation. The grants demonstrate continued commitment and alignment of the CEO with the company's long-term performance, which is generally a neutral to slightly positive signal, but not sufficient to alter a fundamental investment thesis.

Keywords

Harmony Biosciences, HRMY, SEC Form 4, insider transaction, stock options, restricted stock units, equity compensation, CEO, Jeffrey M. Dayno, vesting, tax withholding